Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2025 Filed Jun 9, 2025 20:07 UTC |
Brownlie Keith LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016216 · form4-06092025_080604.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:06 UTC |
Cohen CherylDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016215 · form4-06092025_080601.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 21:02 UTC |
MARINO JAMES JDirector
|
GiftCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027329 · form4-11202024_091142.xml · nonDerivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,204 F1 · shares: This transaction represents a gift transfer to an immediate family member of the reporting person who does not share the same household as the reporting person. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 13:01 UTC |
Marucci Anthony SDirector · PRESIDENT & CEO
|
PurchaseCommon Stock | 11,500 | $26.82 | $308,430.00 |
DisclosureSEC source: 0001415889-24-026489 · form4-11122024_011107.xml · nonDerivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,284 F1 · balance_after: Includes 1,092 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:05 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 16,968 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-24-017363 · form4-06182024_080610.xml · derivative · entry 5 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,632 Underlying: Common Stock · 16,968 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of June 18, 2024, the option is fully vested. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:05 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 3,201 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-24-017363 · form4-06182024_080610.xml · derivative · entry 4 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,201 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:05 UTC |
Martin Samuel BatesSVP AND CFO
|
SaleCommon Stock | 17,172 | $35.42 | $608,314.67 |
DisclosureSEC source: 0001415889-24-017363 · form4-06182024_080610.xml · nonDerivative · entry 3 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,125 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.89 to $35.76 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:05 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionCommon Stock | 16,968 | $10.38 | $176,127.84 |
DisclosureSEC source: 0001415889-24-017363 · form4-06182024_080610.xml · nonDerivative · entry 2 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:05 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionCommon Stock | 3,201 | $9.02 | $28,861.82 |
DisclosureSEC source: 0001415889-24-017363 · form4-06182024_080610.xml · nonDerivative · entry 1 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:04 UTC |
Crowley ElizabethSR. VP & CPDO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-24-017362 · form4-06182024_080610.xml · derivative · entry 3 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 30,000 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: As of June 18, 2024, the option is fully vested. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:04 UTC |
Crowley ElizabethSR. VP & CPDO
|
SaleCommon Stock | 30,000 | $34.87 | $1,045,962.00 |
DisclosureSEC source: 0001415889-24-017362 · form4-06182024_080610.xml · nonDerivative · entry 2 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,074 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.51 to $35.39 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:04 UTC |
Crowley ElizabethSR. VP & CPDO
|
Exercise / conversionCommon Stock | 30,000 | $10.38 | $311,400.00 |
DisclosureSEC source: 0001415889-24-017362 · form4-06182024_080610.xml · nonDerivative · entry 1 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:19 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
GrantIncentive Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017190 · form4-06172024_080643.xml · derivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:18 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
GrantIncentive Stock Option (right to buy) · Derivative | 72,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017186 · form4-06172024_080635.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:17 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
GrantIncentive Stock Option (right to buy) · Derivative | 82,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017184 · form4-06172024_080655.xml · derivative · entry 1 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 82,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:17 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
GrantIncentive Stock Option (right to buy) · Derivative | 78,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017182 · form4-06172024_080619.xml · derivative · entry 1 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:16 UTC |
Crowley ElizabethSR. VP & CPDO
|
GrantIncentive Stock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017179 · form4-06172024_080638.xml · derivative · entry 1 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:16 UTC |
Wright Richard M.SR. VP & CCO
|
GrantIncentive Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017177 · form4-06172024_080608.xml · derivative · entry 1 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:15 UTC |
PEPIN RONALDSR. VP & CBO
|
GrantIncentive Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017175 · form4-06172024_080640.xml · derivative · entry 1 PEPIN RONALD · CIK 0001214504 · SR. VP & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:13 UTC |
Martin Samuel BatesSVP AND CFO
|
GrantIncentive Stock Option (right to buy) · Derivative | 81,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017163 · form4-06172024_080654.xml · derivative · entry 1 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:13 UTC |
KELER TIBOREXECUTIVE VP & CSO
|
GrantIncentive Stock Option (right to buy) · Derivative | 93,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017161 · form4-06172024_080615.xml · derivative · entry 1 KELER TIBOR · CIK 0001429931 · EXECUTIVE VP & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:12 UTC |
Marucci Anthony SDirector · PRESIDENT & CEO
|
GrantIncentive Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017159 · form4-06172024_080622.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:11 UTC |
Jain RitaDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017158 · form4-06172024_080640.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:10 UTC |
NEIL GARRY ARTHURDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017155 · form4-06172024_080651.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:10 UTC |
Cohen CherylDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017153 · form4-06172024_080620.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:08 UTC |
Brownlie Keith LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017151 · form4-06172024_080643.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:04 UTC |
MARINO JAMES JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017141 · form4-06172024_080622.xml · derivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:03 UTC |
CONRAD HERBERT JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017140 · form4-06172024_080647.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:03 UTC |
Shoos Karen L.Director
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017138 · form4-06172024_080614.xml · derivative · entry 1 Shoos Karen L. · CIK 0001255681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:02 UTC |
PENNER HARRY JRDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017137 · form4-06172024_080638.xml · derivative · entry 1 PENNER HARRY JR · CIK 0001131148 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:05 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
Exercise / conversionIncentive Stock Option · Derivative | 15,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001415889-24-016651 · form4-06132024_080617.xml · derivative · entry 2 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: As of July 8, 2023, the option is fully vested. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:05 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
Exercise / conversionCommon Stock | 15,000 | $2.71 | $40,650.00 |
DisclosureSEC source: 0001415889-24-016651 · form4-06132024_080617.xml · nonDerivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:02 UTC |
Crowley ElizabethSR. VP & CPDO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-24-016345 · form4-06112024_080653.xml · derivative · entry 5 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:02 UTC |
Crowley ElizabethSR. VP & CPDO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-24-016345 · form4-06112024_080653.xml · derivative · entry 4 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,500 Underlying: Common Stock · 7,500 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:02 UTC |
Crowley ElizabethSR. VP & CPDO
|
SaleCommon Stock | 15,000 | $35.06 | $525,873.00 |
DisclosureSEC source: 0001415889-24-016345 · form4-06112024_080653.xml · nonDerivative · entry 3 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,074 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.86 to $35.59 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:02 UTC |
Crowley ElizabethSR. VP & CPDO
|
Exercise / conversionCommon Stock | 7,500 | $9.02 | $67,623.75 |
DisclosureSEC source: 0001415889-24-016345 · form4-06112024_080653.xml · nonDerivative · entry 2 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:02 UTC |
Crowley ElizabethSR. VP & CPDO
|
Exercise / conversionCommon Stock | 7,500 | $10.38 | $77,850.00 |
DisclosureSEC source: 0001415889-24-016345 · form4-06112024_080653.xml · nonDerivative · entry 1 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:01 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
SaleCommon Stock | 45,000 | $35.26 | $1,586,844.00 |
DisclosureSEC source: 0001415889-24-016344 · form4-06112024_080650.xml · nonDerivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,115 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.67 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:05 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 9,540 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-24-015950 · form4-06072024_080609.xml · derivative · entry 2 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,454 Underlying: Common Stock · 9,540 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:05 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
Exercise / conversionCommon Stock | 9,540 | $10.38 | $99,025.20 |
DisclosureSEC source: 0001415889-24-015950 · form4-06072024_080609.xml · nonDerivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 58,369 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-24-015544 · form4-06052024_080636.xml · derivative · entry 5 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,023 Underlying: Common Stock · 58,369 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 6,289 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-24-015544 · form4-06052024_080636.xml · derivative · entry 4 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,289 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
SaleCommon Stock | 58,369 | $33.65 | $1,964,087.67 |
DisclosureSEC source: 0001415889-24-015544 · form4-06052024_080636.xml · nonDerivative · entry 3 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,383 F1 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.27 to $34.08 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.27 to $34.08 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.27 to $34.08 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
Exercise / conversionCommon Stock | 58,369 | $10.38 | $605,870.22 |
DisclosureSEC source: 0001415889-24-015544 · form4-06052024_080636.xml · nonDerivative · entry 2 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
Exercise / conversionCommon Stock | 6,289 | $9.02 | $56,704.77 |
DisclosureSEC source: 0001415889-24-015544 · form4-06052024_080636.xml · nonDerivative · entry 1 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC |
Wright Richard M.SR. VP & CCO
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 18,375 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-24-015543 · form4-06052024_080641.xml · derivative · entry 8 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,625 Underlying: Common Stock · 18,375 shares Expires 2032-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC |
Wright Richard M.SR. VP & CCO
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 28,469 | $0.00 Strike: $28.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015543 · form4-06052024_080641.xml · derivative · entry 7 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,531 Underlying: Common Stock · 28,469 shares Expires 2031-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% vested on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC |
Wright Richard M.SR. VP & CCO
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 20,625 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-24-015543 · form4-06052024_080641.xml · derivative · entry 6 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,625 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of June 19, 2023, the option is fully vested. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC |
Wright Richard M.SR. VP & CCO
|
SaleCommon Stock | 19,264 | $33.99 | $654,694.75 |
DisclosureSEC source: 0001415889-24-015543 · form4-06052024_080641.xml · nonDerivative · entry 5 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,833 F2 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.815 to $34.20 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.815 to $34.20 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.815 to $34.20 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC |
Wright Richard M.SR. VP & CCO
|
SaleCommon Stock | 27,580 | $33.53 | $924,658.11 |
DisclosureSEC source: 0001415889-24-015543 · form4-06052024_080641.xml · nonDerivative · entry 4 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,097 F1 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.81 to $33.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.81 to $33.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.81 to $33.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.